Global Monogenic Disease Testing Market, By Test Type (Carrier Testing, Diagnostic Testing, New-Born Screening, Predictive and Pre-Symptomatic Testing, Prenatal Testing), Disease Type (Cystic fibrosis, Sickle Cell Anemia, Severe Combined Immunodeficiency (SCID), Tay-Sachs Disorder, Polycystic Kidney Disorder, Gaucher's Disease, Huntington's Disease, Neurofibromatosis, Thalassaemia, Familial Hypercholesterolemia), End Use (Hospitals, Ambulatory Surgical Centers, Specialized Clinics) – Industry Trends and Forecast to 2029.
Monogenic Disease Testing Market Analysis and Size
Preimplantation genetic testing for monogenic diseases (PGT-M) was introduced as a preventive test in assisted reproductive programmes for patients identified as having a high risk for inherited Mendelian conditions. A single gene mutation in a person's DNA sequence causes monogenic diseases. They can cause birth defects, intellectual, sensory or motor disability. These diseases have an impact on the quality of life and lifespan of those who are affected. Monogenic diseases, unfortunately, have no treatment or cure.
Data Bridge Market Research analyses that the monogenic disease testing market which is expected to reach at a CAGR of 11% during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Monogenic Disease Testing Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Test Type (Carrier Testing, Diagnostic Testing, New-Born Screening, Predictive and Pre-Symptomatic Testing, Prenatal Testing), Disease Type (Cystic fibrosis, Sickle Cell Anemia, Severe Combined Immunodeficiency (SCID), Tay-Sachs Disorder, Polycystic Kidney Disorder, Gaucher's Disease, Huntington's Disease, Neurofibromatosis, Thalassaemia, Familial Hypercholesterolemia), End Use (Hospitals, Ambulatory Surgical Centers, Specialized Clinics)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Celera Support Services (U.S.), Abbott (U.S.), ELITech Group (U.S.), Quest Diagnostics Incorporated (U.S.), Auto Genomics (U.S.), PerkinElmer Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Monogenetic disorders are inherited due to a single defective gene on the autosomes, according to Mendel's Laws. Monogenic disorders are caused by a single mutated gene that can be found on either one or both chromosomes. This disorder affects both men and women equally, because of autosomal conditions. Cystic fibrosis, sickle cell anaemia, SCID, Tay-sachs disease, polycystic kidney disease, Gaucher's disease, Huntington's disease, neurofibromatosis, thalassaemia, and familial hypercholesterolemia are among the common monogenic disorders for which tests are available.
Global Monogenic Disease Testing Market Dynamics
Drivers
- Rising monogenic disorders
The monogenic disorder is caused by a leucine for serine substitution at codon 810 of the MR. 15. This mutation changes the shape and specificity of the MR and eliminates the usual requirement for the 21-hydroxyl group of aldosterone to interact with the MR, which explains other steroids, such as progesterone, activate the MR and spironolactone, which is normally an antagonist of the MR, acts as an agonist in this disorder. All these are the factors which boost the growth of the market.
- Increased usage of monogenic disease testing
The highly developed technological platforms and enhanced genomic tools are expected to have a significant impact on the monogenic disease testing market in the forecast period of 2022 to 2029. Another significant reason for the increased usage of monogenic disease testing has been the increased exclusive opportunity that require more research on monogenic disease tests.
Opportunities
- Technological advancements
The rising prevalence of monogenic disorders around the world will provide ample opportunities for the growth of the monogenic disease testing market during the forecast period. For instance, CACNA1A (FHM1), which is located on chromosome 19p13 and codes for the 1 subunit of neuronal CaV2.1 (P/Q-type) voltage-gated calcium channels, was the first FHM gene discovered. These channels can be found all over the CNS. FHM has been linked to over 20 different missense mutations in this gene. Aside from hemiplegic migraine, these mutations are frequently linked to other phenotypes such as cerebellar ataxia and epilepsy.
Restraints/Challenges
- Lack of trained professionals
Lack of trained professionals and dearth of knowledge, a false result can destroy a person's life and can even lead home to death ill obstruct the market's growth rate.
This monogenic disease testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the monogenic disease testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Monogenic Disease Testing Market Scope
The monogenic disease testing market is segmented on the basis of test type, disease type and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Test Type
- Carrier Testing
- Diagnostic Testing
- New-Born Screening
- Predictive and Pre-Symptomatic Testing
- Prenatal Testing
Disease Type
- Cystic fibrosis
- Sickle Cell Anemia
- Severe Combined Immunodeficiency (SCID)
- Tay-Sachs Disorder
- Polycystic Kidney Disorder
- Gaucher's Disease
- Huntington's Disease
- Neurofibromatosis
- Thalassaemia
- Familial Hypercholesterolemia
End Use
- Hospitals
- Ambulatory Surgical Centers
- Specialized Clinics
Monogenic Disease Testing Market Regional Analysis/Insights
The monogenic disease testing market is analysed and market size insights and trends are provided by country, test type, disease type and end use as referenced above.
The countries covered in the monogenic disease testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the monogenic disease testing market due to the high degree of intelligence and growing awareness amongst people regarding to the monogenic disease testing procedures.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 owing to the presence of a substantial number of organizations that are focusing on disease management.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The monogenic disease testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for monogenic disease testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the monogenic disease testing market. The data is available for historic period 2010-2020.
Competitive Landscape and Monogenic Disease Testing Market Share Analysis
The monogenic disease testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to monogenic disease testing market.
Some of the major players operating in the monogenic disease testing market are:
- Celera Support Services (U.S.)
- Abbott (U.S.)
- ELITech Group (U.S.)
- Quest Diagnostics Incorporated (U.S.)
- Auto Genomics (U.S.)
- PerkinElmer Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Bio-Rad Laboratories, Inc. (U.S.)
- Thermo Fisher Scientific, Inc. (U.S.)
SKU-